Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “XLP”

37 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 37 results

Large-scale testing (Phase 3)Study completedNCT03512314
What this trial is testing

Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency As Open Label Extension

Who this might be right for
XIAP DeficiencyNLRC4-MAS
AB2 Bio Ltd. 11
Early research (Phase 1)Study completedNCT03022799
What this trial is testing

Phase I, KM-819 in Healthy Subjects for Parkinson's Disease

Who this might be right for
Parkinson's Disease
Kainos Medicine Inc. 88
Testing effectiveness (Phase 2)Active Not RecruitingNCT01821781
What this trial is testing

Immune Disorder HSCT Protocol

Who this might be right for
Immune Deficiency DisordersSevere Combined ImmunodeficiencyChronic Granulomatous Disease+11 more
Washington University School of Medicine 20
Large-scale testing (Phase 3)Study completedNCT03113760
What this trial is testing

Therapeutic Use of Tadekinig Alfa in NLRC4 Mutation and XIAP Deficiency

Who this might be right for
NLRC4-MASXIAP Deficiency
AB2 Bio Ltd. 15
Large-scale testing (Phase 3)Study completedNCT06309823
What this trial is testing

A Single-patient Clinical Trial of MAS825 in a Patient With XIAP Deficiency

Who this might be right for
X-linked Lymphoproliferative Syndrome Type 2 (XLP-2)
The Hospital for Sick Children 1
Large-scale testing (Phase 3)Active Not RecruitingNCT06910358
What this trial is testing

Study of Bitopertin in Participants With EPP or XLP (APOLLO)

Who this might be right for
Erythropoietic Protoporphyria (EPP)X-Linked Protoporphyria (XLP)
Disc Medicine, Inc 183
Testing effectiveness (Phase 2)UnknownNCT02828878
What this trial is testing

Prevention of Acute Graft Versus Host Disease in Patients Undergoing Allogeneic ApoGraft Stem Cell Transplantation

Who this might be right for
Hematological Malignancies
Cellect Biotechnology 12
Early research (Phase 1)Active Not RecruitingNCT00710892
What this trial is testing

CASPALLO: Allodepleted T Cells Transduced With Inducible Caspase 9 Suicide Gene

Who this might be right for
Acute Lymphoblastic LeukemiaNon-Hodgkin's LymphomaMyelodysplastic Syndrome+1 more
Baylor College of Medicine 10
Not applicableLooking for participantsNCT01561157
What this trial is testing

Longitudinal Study of the Porphyrias

Who this might be right for
Acute PorphyriasCutaneous Porphyrias
The American Porphyrias Expert Collaborative 1,500
Post-approval studies (Phase 4)Study completedNCT00893425
What this trial is testing

Effect of Renin Angiotensin System Blockade on the Fas Antigen (CD95) and Asymmetric Dimethylarginine (ADMA) Levels in Type-2 Diabetic Patients With Proteinuria

Who this might be right for
ProteinuriaDiabetic NephropathyChronic Kidney Disease
Gulhane School of Medicine 78
Large-scale testing (Phase 3)Looking for participantsNCT07820085
What this trial is testing

Investigate PORT-77 Oral Dosing Compared With Placebo in Participants With Erythropoietic Protoporphyria (EPP) or X-linked Protoporphyria (XLP)

Who this might be right for
Erythropoietic Protoporphyria (EPP)X-Linked Protoporphyria (XLP)EPP2
Portal Therapeutics, Inc. 225
Testing effectiveness (Phase 2)Looking for participantsNCT06730126
What this trial is testing

Study of the ITK Inhibitor Soquelitinib to Reduce Lymphoproliferation and Improve Cytopenias in Autoimmune Lymphoproliferative Syndrome (ALPS)-FAS Patients

Who this might be right for
Autoimmune Lymphoproliferative Syndrome
National Institute of Allergy and Infectious Diseases (NIAID) 15
Testing effectiveness (Phase 2)Looking for participantsNCT01962415
What this trial is testing

Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT

Who this might be right for
Primary Immunodeficiency (PID)Congenital Bone Marrow Failure SyndromesInherited Metabolic Disorders (IMD)+4 more
Paul Szabolcs 100
Not applicableEnded earlyNCT00006054
What this trial is testing

Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies

Who this might be right for
Immunologic Deficiency SyndromesChediak-Higashi SyndromeCommon Variable Immunodeficiency+11 more
Fairview University Medical Center
Early research (Phase 1)Looking for participantsNCT07433621
What this trial is testing

Quercetin in Patients With XIAP (X-linked Inhibitor of Apoptosis) Deficiency

Who this might be right for
XIAP Deficiency
Children's Hospital Medical Center, Cincinnati 12
Not applicableEnrolling By InvitationNCT02422875
What this trial is testing

Comparative Autoantibody and Immunologic Cell Marker Study

Who this might be right for
Autoimmune DiseasesLupus Erythematosus, SystemicCommunicable Diseases
Emory University 2,500
Large-scale testing (Phase 3)Study completedNCT06144840
What this trial is testing

INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP

Who this might be right for
Erythropoietic Protoporphyria (EPP)X-Linked Protoporphyria (XLP)
Tanabe Pharma America, Inc. 165
Testing effectiveness (Phase 2)Study completedNCT00392951
What this trial is testing

Sirolimus for Autoimmune Disease of Blood Cells

Who this might be right for
Autoimmune PancytopeniaAutoimmune Lymphoproliferative Syndrome (ALPS)Evans Syndrome+6 more
Children's Hospital of Philadelphia 30
Early research (Phase 1)Study completedNCT00065390
What this trial is testing

Pyrimethamine to Treat Autoimmune Lymphoproliferative Syndrome

Who this might be right for
Autoimmune DiseaseLymphatic DiseaseLymphoproliferative Disorder
National Institute of Allergy and Infectious Diseases (NIAID) 8
Large-scale testing (Phase 3)Active Not RecruitingNCT05005975
What this trial is testing

Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

Who this might be right for
EPPXLP
Tanabe Pharma America, Inc. 286
Next Page